DSGN
Design Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About DSGN
Design Therapeutics, Inc.
A clinical-stage biotech company that develops treatments for serious degenerative genetic diseases
6005 Hidden Valley Road, Suite 110, Carlsbad, California 92011
--
Design Therapeutics, Inc. was incorporated on December 18, 2017 under the laws of the State of Delaware. They are a clinical-stage biopharmaceutical company pioneering new small molecule therapeutic candidates, called GeneTACs, designed for disease treatment. Certain nucleotide repeat amplification diseases, such as FA, can lead to decreased expression of specific mRNAs; in other diseases, such as myotonic dystrophy type 1 (DM 1), FECD and Huntington's disease, nucleotide repeat amplification can lead to the production of toxic gene products, usually associated with pathological nuclear lesions. Their genes are designed to selectively bind to gene repeats, regulate gene expression by restoring or blocking mRNA transcription, and restore cell health. As a platform, they believe that GeneTACs have broad potential applicability in single-gene nucleotide repeat amplification diseases.
Company Financials
EPS
DSGN has released its 2025 Q3 earnings. EPS was reported at -0.3, versus the expected -0.34, beating expectations. The chart below visualizes how DSGN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
